Akses internasional
Pengobatan kanker di Jerman
Pusat kanker akademik dan uji klinis multisenter.
Informasi orientasi, bukan jaminan akses
Fasilitas
Profil referensi publik
Daftar ini tidak menyatakan kemitraan, kualitas, jadwal, harga, atau penerimaan pasien internasional.
NO DATA
Belum ada profil fasilitas yang lolos model referensi publik untuk negara ini.
Registri publik
Uji klinis yang tercatat
Jumlah uji klinis yang tersedia dihitung dari registri publik dan dapat berubah setiap waktu. Angka di halaman ini mengikuti data registri terakhir yang diambil.
NCT06452277Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT06452277Not verified
NCT04928846Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer | biomarker: EGFR, MET | Chemotherapy
United States, Argentina, Australia +29317 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT04928846Not verified
NCT05326308Not listed
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Austria, Germany2 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT05326308Not verified
NCT05519085Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Multiple Myeloma | Targeted therapy
United States, Argentina, Australia +26266 registry sites
- Registry
- Unknown
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 10 September 2026Source ClinicalTrials.govNCT05519085Not verified
Hal yang perlu dikonfirmasi
- • Persyaratan visa, izin tinggal, dan syarat masuk untuk keperluan medis harus diperiksa pada kanal resmi negara terkait dan kedutaan. TanyaKanker tidak memberikan jaminan penerimaan.
- • Ketersediaan layanan, estimasi tertulis, hal yang termasuk dan tidak termasuk.
- • Rencana tindak lanjut setelah kembali ke Indonesia.
Tanyakan akses di Jerman
Susun kasus dan pertanyaan tanpa janji penerimaan, harga, atau hasil pengobatan.
Nomor navigator belum dikonfigurasi